|
analgesia |
18 |
|
propofol |
13 |
|
pain |
9 |
|
dexmedetomidine |
8 |
|
health economic analysis |
7 |
|
morphine consumption |
7 |
|
neuropathic pain |
7 |
|
placebo |
7 |
|
rct |
7 |
|
apoptosis |
6 |
|
endothelin-1 |
6 |
|
general anesthesia |
6 |
|
opioid |
6 |
|
postoperative pain |
6 |
|
remifentanil |
6 |
|
spinal cord stimulation |
6 |
|
acute postoperative pain |
5 |
|
chronic pain |
5 |
|
dental |
5 |
|
diabetes |
5 |
|
diabetes mellitus |
5 |
|
fbxo9 |
5 |
|
glycogen synthase kinase |
5 |
|
heme oxygenase-1 |
5 |
|
infarct size |
5 |
|
inflammatory pain |
5 |
|
intranasal |
5 |
|
ischemia reperfusion injury |
5 |
|
janus-activated kinase |
5 |
|
myocardial hypertrophy and dysfunction |
5 |
|
myocardial ischemia injury |
5 |
|
neural crest progenitors |
5 |
|
neurog2 |
5 |
|
signal transducer and activator of transcription 3 |
5 |
|
sox10 |
5 |
|
total intravenous anesthesia |
5 |
|
acupuncture analgesia |
4 |
|
acute |
4 |
|
adiponectin |
4 |
|
adipor |
4 |
|
adult |
4 |
|
adult population |
4 |
|
aging |
4 |
|
alzheimer's disease |
4 |
|
ampk |
4 |
|
amyloidosis |
4 |
|
astrocytes |
4 |
|
colorectal surgery |
4 |
|
conscious sedation - methods |
4 |
|
dental surgery |
4 |
|
dexmedetomidine - administration and dosage |
4 |
|
distal radial fracture fixation |
4 |
|
dose-response relationship, drug |
4 |
|
electroacupuncture |
4 |
|
general anaesthesia |
4 |
|
heart failure |
4 |
|
human neural stem cells |
4 |
|
hypnotics and sedatives |
4 |
|
inflammation |
4 |
|
infraclavicular nerve block |
4 |
|
ischemic stroke |
4 |
|
local |
4 |
|
midazolam |
4 |
|
molar, third - surgery |
4 |
|
motor neurons |
4 |
|
pain, postoperative - diagnosis - prevention and control |
4 |
|
pluripotent stem cells |
4 |
|
postoperative analgesia |
4 |
|
postoperative opioid consumption |
4 |
|
prevalence |
4 |
|
regional anesthesia |
4 |
|
sevoflurane |
4 |
|
sox9 |
4 |
|
spinal cord injury |
4 |
|
tooth extraction - adverse effects |
4 |
|
acute pain |
3 |
|
adrenergic alpha-2 receptor agonists - pharmacology |
3 |
|
allopurinol |
3 |
|
amp-activated protein kinase |
3 |
|
analgesics, opioid - metabolism - therapeutic use |
3 |
|
anesthesia, local |
3 |
|
aspirin |
3 |
|
astrocyte |
3 |
|
autophagy |
3 |
|
biological effects |
3 |
|
biology |
3 |
|
blood coagulation |
3 |
|
blood loss |
3 |
|
c-jun n-terminal kinase |
3 |
|
cancer |
3 |
|
cancer chemotherapy |
3 |
|
cardiovascular diseases |
3 |
|
chemobrain |
3 |
|
chronic post-ischaemic pain |
3 |
|
chronic post-ischemia pain |
3 |
|
chronic regional pain syndrome |
3 |
|
cognition dysfunction |
3 |
|
colorectal |
3 |
|
cxcl12 |
3 |
|
cxcl12/cxcr4 axis |
3 |
|
cxcr4 |
3 |
|
cytokines and epigenetics |
3 |
|
deamino arginine vasopressin - pharmacology |
3 |
|
desmopressin |
3 |
|
dexmedetomidine - administration and dosage - adverse effects - pharmacology |
3 |
|
diabetic cardiomyopathy |
3 |
|
endothelin type a receptor |
3 |
|
forkhead box protein o1 |
3 |
|
glial–glial crosstalk |
3 |
|
guidelines |
3 |
|
healthcare utilisation |
3 |
|
hemostasis - drug effects |
3 |
|
hypothermia |
3 |
|
hypothermia - blood |
3 |
|
il-6 |
3 |
|
ischemic preconditioning |
3 |
|
liver - blood supply - drug effects - metabolism |
3 |
|
liver diseases - metabolism - prevention and control |
3 |
|
matrix metalloproteinase-2 |
3 |
|
mitochondria |
3 |
|
mortality |
3 |
|
myocardial injury |
3 |
|
myocardial ischemia-reperfusion |
3 |
|
n-methyl-d-aspartate receptors |
3 |
|
neuroinflammation |
3 |
|
neuromodulator |
3 |
|
neuropathic |
3 |
|
nitric oxide synthase - drug effects - metabolism |
3 |
|
non-cancer pain |
3 |
|
nrf2 |
3 |
|
nuclear factor of activated t-cells 5 |
3 |
|
nuclear factor-kappa b |
3 |
|
opioid requirements |
3 |
|
opioid rotation |
3 |
|
opioid therapy |
3 |
|
oxidative stress |
3 |
|
pain management |
3 |
|
pain, postoperative - drug therapy |
3 |
|
painpaired box gene 2 |
3 |
|
parecoxib |
3 |
|
pathological pain |
3 |
|
persistent opioid use |
3 |
|
pharmacogenetics |
3 |
|
pi3k |
3 |
|
polymorphisms |
3 |
|
postoperative |
3 |
|
postoperative outcomes |
3 |
|
pre-emptive |
3 |
|
pten |
3 |
|
spinal cord |
3 |
|
surgical injury |
3 |
|
vascular remodeling |
3 |
|
[ca2+]i |
2 |
|
acute respiratory distress syndrome |
2 |
|
adverse effects |
2 |
|
aged |
2 |
|
allodynia |
2 |
|
analgesic activity |
2 |
|
analgesics, opioid - administration & dosage - adverse effects |
2 |
|
anesthesia recovery period |
2 |
|
anesthesia, dental - methods |
2 |
|
anesthesia, dental/methods |
2 |
|
animal cell |
2 |
|
animal experiment |
2 |
|
animal model |
2 |
|
anti-nociception |
2 |
|
bias (epidemiology) |
2 |
|
blood component transfusion - standards |
2 |
|
cancer-related pain |
2 |
|
cannabinoids |
2 |
|
central nervous system |
2 |
|
chronic non-cancer pain |
2 |
|
coagulopathy |
2 |
|
conscious sedation/methods |
2 |
|
coronavirus |
2 |
|
covid-19 |
2 |
|
deleted in liver cancer 2 (dlc2) |
2 |
|
differentiation |
2 |
|
drug administration schedule |
2 |
|
drug mechanism |
2 |
|
drug resistance - physiology |
2 |
|
elderly patients |
2 |
|
electroencephalography - drug effects |
2 |
|
endothelial cells |
2 |
|
enhanced recovery after surgery |
2 |
|
environmental enrichment |
2 |
|
erythrocyte transfusion |
2 |
|
erythrocyte transfusion - trends |
2 |
|
excitatory amino acid transporter-2 |
2 |
|
female |
2 |
|
fresh-frozen plasma |
2 |
|
get-1 transgenic mouse |
2 |
|
glucagon-like peptide 1-receptor agonists |
2 |
|
glutamate acid decarboxylases |
2 |
|
hemorrhage - etiology - physiopathology - therapy |
2 |
|
high-flow nasal cannula therapy |
2 |
|
histone deacetylase 5 |
2 |
|
humans |
2 |
|
hyperalgesia |
2 |
|
hypnotics and sedatives - administration & dosage - pharmacology |
2 |
|
il-1β |
2 |
|
immune response |
2 |
|
infusions, intravenous - adverse effects - statistics & numerical data |
2 |
|
labor analgesia |
2 |
|
male |
2 |
|
medical audit |
2 |
|
mental recall - drug effects |
2 |
|
meperidine |
2 |
|
meta-analysis |
2 |
|
meta-regression |
2 |
|
metformin |
2 |
|
microgliap38 |
2 |
|
midazolam - administration & dosage - pharmacology |
2 |
|
middle aged |
2 |
|
monitoring, intraoperative - methods |
2 |
|
monosialoganglioside 1 |
2 |
|
morphine |
2 |
|
morphine - administration & dosage - adverse effects |
2 |
|
nerve regeneration |
2 |
|
neural regeneration |
2 |
|
neural stem cells |
2 |
|
neuroprotection |
2 |
|
neurotoxicity |
2 |
|
opioids |
2 |
|
oral oxycodone |
2 |
|
outcome assessment (health care) - methods |
2 |
|
pain measurement - methods |
2 |
|
pain, postoperative - drug therapy - physiopathology - prevention & control |
2 |
|
patient care management |
2 |
|
patient care team |
2 |
|
patient satisfaction |
2 |
|
patient-controlled |
2 |
|
peripheral nervous system |
2 |
|
peripheral neuropathic pain |
2 |
|
pethidine |
2 |
|
plasma |
2 |
|
pneumonia |
2 |
|
post-operative |
2 |
|
postoperative care |
2 |
|
postoperative nausea and vomiting - chemically induced - epidemiology - prevention & control |
2 |
|
pparα modulator |
2 |
|
proliferation |
2 |
|
red blood cells |
2 |
|
respiratory insufficiency - chemically induced - epidemiology - prevention & control |
2 |
|
resuscitation - methods |
2 |
|
retrospective studies |
2 |
|
review |
2 |
|
rhoa rock |
2 |
|
sars-cov-2 |
2 |
|
self administration - adverse effects - statistics & numerical data |
2 |
|
shock, hemorrhagic - epidemiology - therapy |
2 |
|
sodium–glucose co-transporter type 2 inhibitors |
2 |
|
survivors |
2 |
|
time factors |
2 |
|
tooth extraction |
2 |
|
transfusion |
2 |
|
trauma |
2 |
|
treatment outcome |
2 |
|
young adult |
2 |
|
a549 |
1 |
|
acheon |
1 |
|
acute disease |
1 |
|
adrenergic alpha-2 receptor agonists - pharmacology - therapeutic use |
1 |
|
alanine aminotransferase blood level |
1 |
|
alpha-2 agonist |
1 |
|
aminotransferase blood level |
1 |
|
anaesthesiology |
1 |
|
analgesic and antitumor |
1 |
|
analgesics - pharmacology - therapeutic use |
1 |
|
analgesics, opioid - adverse effects - therapeutic use |
1 |
|
anesthetics, intravenous - pharmacology |
1 |
|
angiotensin ii - antagonists & inhibitors - pharmacology |
1 |
|
animal |
1 |
|
animals |
1 |
|
antimetabolites - diagnostic use |
1 |
|
ap-1 |
1 |
|
asia |
1 |
|
atp depletion |
1 |
|
back pain |
1 |
|
behavior change |
1 |
|
blood component transfusion - methods |
1 |
|
blotting, northern |
1 |
|
blotting, western |
1 |
|
bone cancer pain |
1 |
|
bromodeoxyuridine - diagnostic use |
1 |
|
c-jun |
1 |
|
c57bl mouse |
1 |
|
cancer-related fatigue (crf) |
1 |
|
carotid artery puncture |
1 |
|
cell line, tumor |
1 |
|
cell proliferation - drug effects |
1 |
|
cell survival - drug effects |
1 |
|
central venous line cannulation |
1 |
|
chop |
1 |
|
chromatin immunoprecipitation |
1 |
|
chronic |
1 |
|
chronic disease |
1 |
|
clonidine |
1 |
|
cognition |
1 |
|
colon cancer |
1 |
|
colonic neoplasms - genetics - metabolism |
1 |
|
comparative study |
1 |
|
complication |
1 |
|
disease model |
1 |
|
dna, complementary - biosynthesis - genetics |
1 |
|
drug effect |
1 |
|
embolism - microbiology |
1 |
|
endocarditis, bacterial |
1 |
|
endothelin a receptor antagonist |
1 |
|
epidural |
1 |
|
er stress |
1 |
|
erythema - microbiology |
1 |
|
erythrocyte transfusion - methods |
1 |
|
exercise |
1 |
|
external beam radiation therapy (ebrt) |
1 |
|
extracellular signal-regulated map kinases - genetics - metabolism |
1 |
|
fadolmidine |
1 |
|
fibroblasts - drug effects |
1 |
|
fluoresceins |
1 |
|
foot dermatoses - microbiology |
1 |
|
fused furo[2,3-d]pyrimidinone derivatives |
1 |
|
gdnf |
1 |
|
gene expression |
1 |
|
gene expression regulation, enzymologic - drug effects |
1 |
|
glial cell line-derived neurotrophic factor - metabolism - pharmacology |
1 |
|
glioma |
1 |
|
glycolysis |
1 |
|
grp78 |
1 |
|
gsk3α/β |
1 |
|
haemophilus infections |
1 |
|
haemophilus parainfluenzae |
1 |
|
heart rate - drug effects |
1 |
|
heart valve diseases - diagnosis - microbiology |
1 |
|
hemorrhage - etiology - therapy |
1 |
|
internal jugular vein |
1 |
|
ischemia |
1 |
|
jaundice, obstructive - complications |
1 |
|
ketamine |
1 |
|
lymphocyte |
1 |
|
matrix metalloproteinase 13 - genetics - metabolism |
1 |
|
mediator complex - genetics |
1 |
|
medical sciences |
1 |
|
migration |
1 |
|
mirna-23a |
1 |
|
mitochondrial membrane potential |
1 |
|
mitral valve |
1 |
|
mmp-13 |
1 |
|
myocardial contraction - drug effects |
1 |
|
myocardial infarction |
1 |
|
myocardial reperfusion injury |
1 |
|
myocytes, cardiac - drug effects |
1 |
|
nadph oxidase - metabolism |
1 |
|
neural progenitors |
1 |
|
neuralgia |
1 |
|
neuroglia - drug effects - physiology |
1 |
|
neuroplasticity |
1 |
|
nitrates - metabolism |
1 |
|
nitric oxide synthase - metabolism |
1 |
|
nitrites - metabolism |
1 |
|
nlrp3 inflammasome |
1 |
|
oxidation-reduction |
1 |
|
p38 mitogen-activated protein kinase |
1 |
|
pain - drug therapy |
1 |
|
pain - drug therapy - physiopathology - psychology |
1 |
|
palmitic acid |
1 |
|
phloroglucinol - analogs and derivatives - pharmacology |
1 |
|
physicians |
1 |
|
pneumothorax |
1 |
|
positron-emission tomography |
1 |
|
prenyl-phloroglucinol derivatives |
1 |
|
propofol - pharmacology |
1 |
|
prostate cancer |
1 |
|
quality of life |
1 |
|
questionnaire |
1 |
|
rats |
1 |
|
rats, sprague-dawley |
1 |
|
reactive oxygen species |
1 |
|
rna - biosynthesis - isolation & purification |
1 |
|
ros |
1 |
|
sciatic nerve injury |
1 |
|
signalling pathway |
1 |
|
splenic infarction - diagnosis - microbiology |
1 |
|
steroid |
1 |
|
superoxides - metabolism |
1 |
|
synthesis |
1 |
|
tetrandrine |
1 |
|
tomography, x-ray computed |
1 |
|
transcription factor chop/genetics |
1 |
|
transfection |
1 |
|
txnip |
1 |
|
ultrasound |
1 |
|
wounds and injuries - complications - therapy |
1 |
